Mirati Therapeutics Inc.

6 trials 2 recruiting Commercial sponsor

Filter these 6 trials by condition, phase, country and more.

Open in Search →

6 Registered trials

2 Recruiting

4 Completed trials

19 Countries active

18 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 3 Phase II/III: 1 Phase II: 2

Oversight events:

6 temporary halts 11 corrective measures across 3 trials

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 3 Colorectal cancer metastatic 1 Non-small cell lung cancer metastatic 1

Top IMPs

ADAGRASIB 5 DOCETAXEL 2 CETUXIMAB 1 NIVOLUMAB 1 PEMBROLIZUMAB 1 SITRAVATINIB MALATE 1

All trials

6 total

Trial of Two Adagrasib Dosing Regimens in NSCLC with KRAS G12C Mutation Recruiting

2023-503523-25-00 Phase II 9 countries ADAGRASIB
Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma… Recruiting

2023-508922-83-00 Phase II/III 19 countries ADAGRASIB; PEMBROLIZUMAB
A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Ended

2023-503714-77-00 Phase II 6 countries ADAGRASIB
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended

2023-506241-30-00 Phase III 15 countries ADAGRASIB; CETUXIMAB
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation Ended

2023-507263-19-00 Phase III 14 countries ADAGRASIB; DOCETAXEL
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small C… Ended

2024-516598-60-00 Phase III 3 countries DOCETAXEL; NIVOLUMAB; SITRAVATINIB MALATE

Showing 1–6 of 6 trials

← All sponsors A–Z